Retina

The highlights from this year’s meeting, brought to you in conjunction with Modern Retina

The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.

The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

Developing technology may offer marked improvements in surgical precision

This effort will advance screening technology at Canada’s foremost specialist care provider in diabetes and endocrinology.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

A modified endolaser setup was found to be safe and efficient for use during chandelier scleral buckling.

Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.

Investigators emphasised a significant unmet need for home-based monitoring of visual function with patient-centric technologies

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

ARCATUS, also known as XIPERE®, utilises a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"